Loading...

The Scientist

» Big Pharma

Most Recent

The announcement comes after an agency working group recommends against an industry partnership on ethical grounds.

0 Comments

Pharmaceutical giant Sanofi to take over hemophilia drugmaker Biovertiv, while Celgene will buy cancer drugmaker Juno Therapeutics.

0 Comments

image: Dengue Vaccine Program Halted Over Safety Issues

Dengue Vaccine Program Halted Over Safety Issues

By Shawna Williams | December 5, 2017

The drug may worsen future infections for people who haven't already been exposed to the virus.

0 Comments

The Good Pharma Scorecard finds some big pharmaceutical companies are meeting legal standards for disclosing results—but many studies still go unreported.

0 Comments

image: Takeda to Buy Cancer Drug Maker Ariad for $5.2 Billion

Takeda to Buy Cancer Drug Maker Ariad for $5.2 Billion

By Joshua A. Krisch | January 10, 2017

The pharma giant’s purchase of the US firm includes the acquisition of investigative cancer drugs.

0 Comments

image: TS Picks: August 9, 2016

TS Picks: August 9, 2016

By Bob Grant | August 9, 2016

Gene therapy money-back guarantee; the brain benefits from bilingualism; Q&A with a science watchdog

0 Comments

image: Pfizer Scoops Anacor for $5.3 Billion

Pfizer Scoops Anacor for $5.3 Billion

By Bob Grant | May 17, 2016

The acquisition-hungry pharmaceutical firm is purchasing the California-based eczema gel maker.

0 Comments

image: Bayer Enters CRISPR Field

Bayer Enters CRISPR Field

By Karen Zusi | December 22, 2015

The pharmaceutical company will spend $335 million on a new venture with biotech startup CRISPR Therapeutics.

0 Comments

image: Pfizer and Allergan to Merge

Pfizer and Allergan to Merge

By Bob Grant | November 23, 2015

The two drugmakers will join forces in a $160 billion deal—if it’s given the regulatory green light.

0 Comments

image: Shire Buys Rare Disease Drug Developer

Shire Buys Rare Disease Drug Developer

By Tracy Vence | November 2, 2015

The Irish drugmaker is set to acquire the Massachusetts-based Dyax in a $5.9 billion deal.

0 Comments

Popular Now

  1. Human Brain Organoids Thrive in Mouse Brains
  2. Estonia Offers Free Genetic Testing to Residents
  3. Long-Term Study Reveals Flip in Plant Responses to Carbon Dioxide
  4. Jim Bridenstine Confirmed to Lead NASA